Mild alopecia areata
Conditions
Interventions
Application of an appropriate amount of carpronium solution to the affected area twice daily (once in morning and in once evening) for 12 weeks.
In addition to application of an appropriate amount of
Sponsors
Institute of Health Biosciences ,The University of Tokushima Graduate School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients having less than five observed isolated hair loss areas, covering less than 25% 2) Male and female patients aged 20 years or older at time of informed consent 3) Patients who provide written consent of agreement to voluntarily participate in the clinical study
Exclusion criteria
Exclusion criteria: 1)Patients who have advanced eczema and/or dermatitis of the scalp 2)Patients in whom three or more hairs are lost in hair pull test 3)Patients who have received oral steroid treatment, inhalation treatment, local steroid injection, or external steroid treatment for scalp within one month before the date of informed consent 4)Patients who have used medical products that claim promotion of hair growth, prevention of hair loss, or hair restoration action within one month before the date of informed consent 5)Patients with a history of allergic reaction to carpronium or glycyrrhizin 6)Patients diagnosed with malignant tumor 7)Patients with serious liver, renal, or cardiac disease 8)Patients who are breast-feeding, pregnant, possibly pregnant, or plan to become pregnant during the study period 9)In addition, patients who are determined as ineligible by the study doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy after 12 weeks treatment (e.g., doctor's findings, determination of disease course, subject's impression, and photographs of observed lesions) | — |
Countries
Japan
Outcome results
None listed